Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study - PubMed (original) (raw)
Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study
Pier Luigi Zinzani et al. Clin Lymphoma Myeloma. 2009 Oct.
Abstract
Background: Third-generation regimens (MACOP-B [methotrexate/leucovorin (LV)/doxorubicin/cyclophosphamide/vincristine/ prednisone/bleomycin] or VACOP-B [etoposide/LV/doxorubicin/cyclophosphamide/vincristine/prednisone/bleomycin]) in combination with local radiation therapy seem to improve lymphoma-free survival of primary mediastinal large B-cell lymphoma (PMLBCL). Recently, the superiority of R-CHOP (rituximab plus cyclophosphamide/doxorubicin/vincristine/ prednisone) over CHOP-like regimens has been demonstrated in elderly and younger patients with low-risk diffuse large B-cell lymphoma.
Patients and methods: Retrospectively, between February 2002 and July 2006, 45 previously untreated patients with PMLBCL were treated with a combination of a third-generation chemotherapy regimen (MACOP-B or VACOP-B), concurrent rituximab, and mediastinal radiation therapy.
Results: Twenty-six (62%) patients achieved a complete response (CR), and 15 (36%) obtained a partial response after MACOP-B/VACOP-B plus rituximab. After radiation therapy, the CR rate was 80%. At a median follow-up of 28 months, among the 34 patients who obtained a CR, 3 relapsed after 16, 19, and 22 months, respectively. Projected overall survival was 80% at 5 years; the relapse-free survival (RFS) curve of the 34 patients who achieved CR was 88% at 5 years.
Conclusion: In this retrospective study, in patients with PMLBCL, combined-modality treatment using the MACOP-B/VACOP-B regimen plus rituximab induces a high remission rate, with patients having a > 80% chance of surviving relapse free at 5 years. In comparison with historical data on MACOP-B/VACOP-B without rituximab, there are no statistically significant differences in terms of CR and RFS rates.
Similar articles
- Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B.
Todeschini G, Secchi S, Morra E, Vitolo U, Orlandi E, Pasini F, Gallo E, Ambrosetti A, Tecchio C, Tarella C, Gabbas A, Gallamini A, Gargantini L, Pizzuti M, Fioritoni G, Gottin L, Rossi G, Lazzarino M, Menestrina F, Paulli M, Palestro M, Cabras MG, Di Vito F, Pizzolo G. Todeschini G, et al. Br J Cancer. 2004 Jan 26;90(2):372-6. doi: 10.1038/sj.bjc.6601460. Br J Cancer. 2004. PMID: 14735179 Free PMC article. Clinical Trial. - Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy.
Zinzani PL, Martelli M, Bendandi M, De Renzo A, Zaccaria A, Pavone E, Bocchia M, Falini B, Gobbi M, Gherlinzoni F, Stefoni V, Tani M, Tura S. Zinzani PL, et al. Haematologica. 2001 Feb;86(2):187-91. Haematologica. 2001. PMID: 11224489 Clinical Trial. - MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease.
O'Reilly SE, Hoskins P, Klimo P, Connors JM. O'Reilly SE, et al. Ann Oncol. 1991 Jan;2 Suppl 1:17-23. doi: 10.1093/annonc/2.suppl_1.17. Ann Oncol. 1991. PMID: 1710485 - Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR, Cheung MC, Mahrous M, Piliotis E, Berinstein N, Imrie KR, Zhang L, Buckstein R. Guirguis HR, et al. Br J Haematol. 2012 Oct;159(1):39-49. doi: 10.1111/j.1365-2141.2012.09247.x. Epub 2012 Jul 31. Br J Haematol. 2012. PMID: 22849793 Review. - Primary mediastinal large B-cell lymphoma: the need for prospective controlled clinical trials.
Bieri S, Roggero E, Zucca E, Bertoni F, Pianca S, Sanna P, Pedrinis E, Bernier J, Cavalli F. Bieri S, et al. Leuk Lymphoma. 1999 Nov;35(5-6):537-44. doi: 10.1080/10428199909169618. Leuk Lymphoma. 1999. PMID: 10609791 Review.
Cited by
- Improved survival for dose-intensive chemotherapy in primary mediastinal B-cell lymphoma: a systematic review and meta-analysis of 4,068 patients.
Cook MR, Williams LS, Dorris CS, Luo Y, Makambi K, Dunleavy K. Cook MR, et al. Haematologica. 2024 Mar 1;109(3):846-856. doi: 10.3324/haematol.2023.283446. Haematologica. 2024. PMID: 37646662 Free PMC article. - Efficacy of Residual Site Radiation Therapy (ISRT) in Patients with Primary Mediastinal Lymphoma with Deauville Score 4 Following R-CHT: Results of a Retrospective Mono Institutional Study.
Facondo G, Serio M, Vullo G, Bianchi MP, Pelliccia S, Di Rocco A, Lanzolla T, Valeriani M, Di Napoli A, Tafuri A, Martelli M, Osti MF, De Sanctis V. Facondo G, et al. J Clin Med. 2023 May 31;12(11):3777. doi: 10.3390/jcm12113777. J Clin Med. 2023. PMID: 37297971 Free PMC article. - Less Intensive Regimens May Still Be Suitable for the Initial Treatment of Primary Mediastinal B-Cell Lymphoma in Resource-Limited Settings.
Velasques RD, da Silva WF, Bellesso M, Rocha V, Pereira J. Velasques RD, et al. J Oncol. 2022 Jun 6;2022:2099456. doi: 10.1155/2022/2099456. eCollection 2022. J Oncol. 2022. PMID: 35706929 Free PMC article. - Primary mediastinal large B cell lymphoma.
Yu Y, Dong X, Tu M, Wang H. Yu Y, et al. Thorac Cancer. 2021 Nov;12(21):2831-2837. doi: 10.1111/1759-7714.14155. Epub 2021 Sep 29. Thorac Cancer. 2021. PMID: 34590432 Free PMC article. Review. - Outcomes of Patients with Primary Mediastinal B-Cell Lymphoma Treated with Dose Adjusted R-EPOCH Regimen: A Single Centre Experience.
Jain H, Kapoor A, Sengar M, Chanana R, Menon H, Sridhar E, Laskar S, Agarwal A, Shastri J, Khanna N, Rangarajan V, Bagal B, Thorat J, Shet T, Gujral S. Jain H, et al. Indian J Hematol Blood Transfus. 2021 Jul;37(3):379-385. doi: 10.1007/s12288-020-01372-y. Epub 2021 Mar 1. Indian J Hematol Blood Transfus. 2021. PMID: 34267455 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Research Materials